Background
Brian Rifkin
STAMP of Approval: Tacrolimus vs MMF in ...

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome
Background
Cristina Adriana Popa
Advance-HTN: Return of the systolic order – ...

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Background
swapnil hiremath
Double Trouble: ddAVP and the Bleeding Biopsy

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

Double Trouble: ddAVP and the Bleeding Biopsy
Background
Cristina Adriana Popa
Kidney Allografts-Play With Fire, Get Burned

This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…

Kidney Allografts-Play With Fire, Get Burned
Background
swapnil hiremath
Metformin- Should I Stay or Should I Go

This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

Metformin- Should I Stay or Should I Go

sglt2i

Estudio post EMPA-KIDNEY_El Resumen Visual

El estudio post EMPA-KIDNEY, evaluó los efectos de la empagliflozina en pacientes con enfermedad renal crónica. Los hallazgos mostraron que este tratamiento no solo proporcionó beneficios cardiorrenales significativos durante la fase activa del estudio, sino que también mantuvo estos efectos positivos por hasta 12 meses después de la interrupción del tratamiento. 

 Revisa el resumen visual realizado por Oscar Durón y únete a la conversación en nuestro próximo #NephJC

Flozins strike again!

If you missed the biggest NephJC of the year, at least read the highlights here.

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.